Novo Nordisk (HEOR)
About Novo Nordisk
Founded in 1923, Novo Nordisk is a global healthcare company with 100 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help individuals defeat serious chronic diseases such as obesity, MASH, neurodegenerative disease and other rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. Additionally, Novo Nordisk is the first pharmaceutical company to use 100% renewable power in all global production facilities.
About Rutgers HOPE
The Rutgers University Center for Health Outcomes, Policy, and Economics partners with scientists, clinicians and stakeholders from academia, pharmaceutical, biotech, and other marketplace innovators to conduct interdisciplinary research that produces relevant, meaningful health outcomes, economic models and analyses to facilitate the adoption of cost-effective healthcare and improve patient outcomes.
Fellowship Team
Christopher Blanchette, PhD
Fellowship Sponsor | Novo Nordisk Fellowship Director
Chintan Dave, PharmD, PhD
Fellowship Director | Rutgers HOPE Fellowship Director
Abhilasha Ramasamy
Fellowship Preceptor
Mads Faurby
Fellowship Preceptor
Ben Gutierrez
Fellowship Preceptor
Program and Structure
The HOPE–Novo Nordisk Fellowship offers a two-year immersive experience bridging industry and academia. Unlike traditional 1+1 HEOR fellowship models, fellows spend both years embedded at Novo Nordisk while completing an MS through Rutgers HOPE. This sustained experience provides greater continuity, deeper project ownership, and increasing responsibility across the RWE/HEOR evidence lifecycle, from study development through scientific presentation and publication.
-
The Fellow will work closely with colleagues across Novo Nordisk’s Clinical Data Science and Evidence (CDSE) team and the Rutgers HOPE Center to gain comprehensive experience spanning both industry and academia. Fellows will:
- Support HEOR strategy and evidence generation planning process
- Work as a member of the research team on select research projects and interact with cross-functional stakeholders
- Perform analysis using Real World Data to identify factors affecting the use of medications in the target patient population
- Be responsible for data dissemination for specific research projects
- Work with HOPE faculty and research analysts to design and execute an RWE / HEOR project using large databases (e.g., Medicare, Medicaid, MarketScan, CPRD, SEER-Medicare)
- Complete the bulk of coursework focused on real-world evidence, pharmacoeconomics, and outcomes research through the Rutgers MS-HOPE program
- Engage in academic writing, dissemination, and professional development alongside HOPE core faculty and the CDSE team
-
During the second year, the Fellow will advance from foundational training to scientific and project leadership, building on the experience gained in Year 1. Key responsibilities include:
- Deepen expertise in HEOR and evidence generation through advanced coursework and applied project work
- Lead components of real-world evidence (RWE) research projects, including managing vendor calls, tracking timelines, and coordinating deliverables
- Communicate scientific insights and project progress with key opinion leaders (KOLs) and cross-functional teams
- Mentor and support the first-year Fellow in project execution and professional development
- Complete the Rutgers MS-HOPE program, focusing on final coursework and capstone completion
- Partner with the CDSE team and HOPE faculty to publish a first-author manuscript and present findings at national and international conferences
Fellow Perspective
 Sarah Gutman, PharmD, MSc Rare Disease TA “Sarah is a first-year fellow at Rutgers HOPE and Novo Nordisk, and she earned her PharmD from Rutgers University in 2026. Her interest for HEOR developed during a pharmacoeconomic modeling course where she performed a cost-effectiveness analysis on diagnostic tests in Alzheimer’s Disease. Later on, Sarah held an externship in Global Market Access & HEOR at GlaxoSmithKline where she aided in statistical analysis planning for a Phase III global asset, literature reviews and gained exposure to HTA systems and value propositions at local and regional levels. In her current role, she supports cross-functional and launch-ready projects, generating real-world evidence for a Phase III asset. Sarah is eager to make strides in her knowledge and application of HEOR while making meaningful contributions to her team at Novo Nordisk.” |
 Jessica Muth, PharmD, MSc Obesity TA “Jessica is a second-year fellow at Rutgers HOPE and Novo Nordisk. She earned her PharmD from Rutgers University in 2025. Her passion for HEOR stems from her early experiences conducting pharmacoepidemiologic research and economic modeling, where she evaluated the cost effectiveness of diagnostic therapies for Alzheimer’s disease. She also gained exposure to global HEOR and market access through a pharmacy school externship, supporting the development of payer-relevant evidence for an HTA submission. In her current role as a fellow, she works on cross-functional projects that integrate real-world evidence and strategic planning to support the US obesity therapeutic area at Novo Nordisk. At Rutgers, under the guidance of Dr. Chintan Dave, she conducts comparative effectiveness research using real-world data on chronic disease management. Jessica is eager to continue expanding her HEOR expertise and contribute to meaningful, data-driven healthcare decision-making.” |
Previous Fellows
Julia Wang, PharmD, MS
First Position: Senior Manager (Contractor), Novo Nordisk
Aarth Sheth, PharmD
First Position: Associate Director, Bausch Health
Sunny Sheth, PharmD
First Position: Manager, Novo Nordisk
Tarlan Namvar, PharmD
First Position: Senior Manager, Abbott
Ashley Guesnier, PharmD
First Position: Associate Manager, Stratevi
